Literature DB >> 641397

Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation.

D F Mosher, E M Williams.   

Abstract

Plasma fibronectin (cold-insoluble globulin) is known to be cross-linked to fibrin during the final stage of blood coagulation and is probably the major nonspecific opsonin of blood. We measured the concentration of plasma fibronectin in 36 hospitalized patients (11 with malignancy, 12 with infection, 13 with other underlying diseases) with evidence of fibrin depostion and lysis. Plasma fibronectin concentration was greater than 2 S.D. below the mean of normals in 17 of the patients (p less than 0.001). Depression of fibronectin was not related to severity of disseminated intravascular coagulation, as assessed by fibrinogen concentration and the quantity of FDP in serum. Depressed plasma fibronectin concentration and the quantity of FDP in serum. Depressed plasma fibronectin concentration was an unfavorable prognostic finding, inasmuch as 12 of the 17 patients with depressed fibronectin concentrations died during hospitalization as compared to five of the 19 patients with normal fibronectin concentrations (p less than 0.02). We speculate that specific depletion of plasma fibronectin, because of codeposition with fibrin or due to increased utilization as a nonspecific opsonin, may contribute to the organ failure seen in severely ill patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 641397

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  37 in total

1.  Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi.

Authors:  Jaehyung Cho; Deane F Mosher
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

2.  Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms.

Authors:  Jeniel E Nett; Jonathan Cabezas-Olcoz; Karen Marchillo; Deane F Mosher; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Plasma fibronectin concentrations in healthy and septic infants.

Authors:  M Domula; K Bykowska; Z Wegrzynowicz; S Lopaciuk; G Weissbach; M Kopéc
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

4.  Fibronectin and Kupffer cell function in fulminant hepatic failure.

Authors:  M Imawari; R D Hughes; C D Gove; R Williams
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Plasma fibronectin in psoriatic arthritis subgroups.

Authors:  M Cutolo; S Accardo; M A Cimmino; S Rovida
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

6.  Plasma fibronectin in normal subjects and in various disease states.

Authors:  N E Stathakis; A Fountas; E Tsianos
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

7.  Human fibronectin metabolism.

Authors:  B A Pussell; P W Peake; M A Brown; J A Charlesworth
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 8.  Fibronectin and the critically ill patient: current status.

Authors:  T M Saba; J L Kiener; J M Holman
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

9.  Fibronectin in chronic inflammation: studies using the rat air pouch model of chronic allergic inflammation.

Authors:  D L Scott; M W Robinson; S Yoshino
Journal:  Br J Exp Pathol       Date:  1985-10

10.  Plasma fibronectin concentrations in patients with HIV infection and visceral leishmaniasis.

Authors:  A Rodríguez-Cuartero; J Nuñez-Carrill; A Salas-Galán; M A Rodríguez-Rodríguez
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.